UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pharmacotherapy for co-occurring schizophrenia and substance use disorder

Authors
E Cabrina Campbell, MD
Stanley N Caroff, MD
Stephan C Mann, MD, DLFAPA
Section Editors
Andrew J Saxon, MD
Stephen Marder, MD
Deputy Editor
Richard Hermann, MD

INTRODUCTION

Schizophrenia and addiction are both chronic disorders with serious complications, consequences, and costs for individuals and society. Both conditions are associated with poor adherence to treatment and poorer outcomes when the co-occurring disorder is present.

Some of the symptoms of schizophrenia overlap with symptoms of intoxication, chronic substance use, or withdrawal from alcohol or other drugs. Family history and the temporal relationship of symptoms can help to distinguish patients with a substance use disorder (SUD) alone from co-occurring schizophrenia and SUD.

Pharmacotherapy of co-occurring schizophrenia and SUD are described here. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and psychosocial interventions for co-occurring schizophrenia and SUD are described separately. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis and treatment of schizophrenia or SUD individually (not co-occurring) are also discussed separately.

(See "Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis".)

(See "Psychosocial interventions for co-occurring schizophrenia and substance use disorder".)

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon May 16 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry 2009; 17:24.
  2. Fryers T, Melzer D, Jenkins R, Brugha T. The distribution of the common mental disorders: social inequalities in Europe. Clin Pract Epidemiol Ment Health 2005; 1:14.
  3. Scott KM, Al-Hamzawi AO, Andrade LH, et al. Associations between subjective social status and DSM-IV mental disorders: results from the World Mental Health surveys. JAMA Psychiatry 2014; 71:1400.
  4. Brown T, Platt S, Amos A. Equity impact of European individual-level smoking cessation interventions to reduce smoking in adults: a systematic review. Eur J Public Health 2014; 24:551.
  5. Bull ER, Dombrowski SU, McCleary N, Johnston M. Are interventions for low-income groups effective in changing healthy eating, physical activity and smoking behaviours? A systematic review and meta-analysis. BMJ Open 2014; 4:e006046.
  6. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005; 11:315.
  7. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000; 26:105.
  8. Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2013; :CD001088.
  9. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academies Press, Washington DC 2006. p.210.
  10. De Witte NA, Crunelle CL, Sabbe B, et al. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res 2014; 20:105.
  11. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006; 26:9.
  12. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005; 193:379.
  13. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54:253.
  14. Sevy S, Robinson DG, Sunday S, et al. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res 2011; 188:310.
  15. Brunetti M, Di Tizio L, Dezi S, et al. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci 2012; 16:1346.
  16. Kerfoot KE, Rosenheck RA, Petrakis IL, et al. Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res 2011; 132:177.
  17. Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res 2008; 100:39.
  18. Rheimerr F, Swartz MS, Olsen JL. Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. In: Antipsychotic Trials in Schizophrenia: The CATIE Project, Stroup TS, Lieberman JA. (Eds), Cambridge University Press, New York 2006. p.189.
  19. Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res 2013; 147:132.
  20. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085.
  21. Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am 2009; 32:821.
  22. Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, et al. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med 2014; 44:37.
  23. Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25:1158.
  24. Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:984.
  25. Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 2014; 23:308.
  26. Brunette MF, Dawson R, O'Keefe CD, et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn 2011; 7:50.
  27. Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry 2015; 76:1359.
  28. Leatherman SM, Liang MH, Krystal JH, et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis 2014; 202:13.
  29. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991; 84:272.
  30. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992; 8:93.
  31. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15:469.
  32. Jin Y, Pollock BG, Coley K, et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 2010; 50:73.
  33. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990; 16:57.
  34. Potvin S, Pampoulova T, Mancini-Marië A, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77:796.
  35. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80:33.
  36. Zhornitsky S, Stip E, Pampoulova T, et al. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord 2010; 25:2188.
  37. Jones RM, Lichtenstein P, Grann M, et al. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. J Clin Psychiatry 2011; 72:775.
  38. Khokhar JY, Chau DT, Dawson R, Green AI. Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug Alcohol Depend 2015; 152:277.
  39. Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013; 23:1401.
  40. Mohamed S, Rosenheck RA, Lin H, et al. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. J Nerv Ment Dis 2015; 203:486.
  41. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32:637.
  42. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013; :CD007253.
  43. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 46:125.
  44. de Leon J, Diaz FJ, Josiassen RC, et al. Does clozapine decrease smoking? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:757.
  45. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005; 25:363.
  46. Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenia patients. Eur Neuropsychopharmacol 1996; 6:43.
  47. Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003; 33:85.
  48. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26:441.
  49. Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry 2012; 73:e1039.
  50. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145.
  51. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295:321.
  52. Mackowick KM, Barr MS, Wing VC, et al. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52:79.
  53. Toffey BA, Rabin M, Kurlan R. Withdrawal-Emergent Dyskinesias following Varenicline Therapy. Open Neurol J 2015; 9:7.
  54. Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21:195.
  55. Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007; 68:410.
  56. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993; 34:713.
  57. Quik M, Bordia T, Zhang D, Perez XA. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. Int Rev Neurobiol 2015; 124:247.
  58. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Safety Newsletter 2009; 2:1. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf (Accessed on September 20, 2011).
  59. Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011; 6:e27016.
  60. Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350:h1109.
  61. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.
  62. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006; 32:644.
  63. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004; 172:291.
  64. Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003; 12:242.
  65. Ralevski E, O'Brien E, Jane JS, et al. Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Ment Dis 2011; 199:499.
  66. Schöpf J, Hucker H. Baclofen in the treatment of schizophrenia: a pilot study. Pharmakopsychiatr Neuropsychopharmakol 1977; 10:89.
  67. McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev 2014; :CD004837.
  68. Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992; 28:309.
  69. Siris SG, Mason SE, Bermanzohn PC, et al. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993; 29:127.
  70. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; :CD002209.
  71. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; :CD002207.